

Risperidone

Selected References:

- Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. *Drug Saf*; 30(3):247-264.
- Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. *J Affect Disord*; 373:495-504.
- Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. *CNS Drugs*; 32:351-366.
- Eberhard J., et al. 2007. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. *Acta Psychiatrica Scandinavica*; 115(4), 268-276.
- Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. *Basic & Clinical Pharmacology & Toxicology*; 116:315-320.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. *Am J Obstet Gynecol*; 190:435-441.
- Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. *J Clin Psychopharmacol*; 33:453-462.
- Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. *JAMA Psychiatry*; 73(9): 938-946.
- National Library of Medicine. 2026. Drug labeling information (section 8.2). DailyMed. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6767972-2d3f-482b-80bd-ac93e28fdd05&type=display#section-8.2>
- McAllister-Williams RH, et al. 2017. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. *J Psychopharmacol*; 31(5): 519-552.
- Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. *Am J Psychiatry*; 175(6):564-574.
- Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. *Health Technol Assess*; 20:1-176
- Straub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. *JAMA Intern Med*; 182(5):522-533.
- Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. *J Clin Psychopharmacol*; 36(3):244-252.
- Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. *Breastfeed Med*; 14:683-684.
- Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. *BMJ*; 350:h2298.
- Wang E, et al. 2025. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *CNS Drugs*; 39(1):1-22.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Risperidone

Selected References:

- ACOG Committee Opinion No 804. 2020. Physical Activity and Exercise During Pregnancy and the Postpartum Period. *Obstet Gynecol*; 135(4):e178-188.
- ACOG. 2022. Exercise During Pregnancy. Frequently asked questions. Available at: <https://www.acog.org/womens-health/faqs/exercise-during-pregnancy> [Accessed 3/2026].
- Artal R. 2016. Exercise in Pregnancy: Guidelines. *Clin Obstet Gynecol*. 59(3):639-644.
- Barakat R, Perales M. 2016. Resistance Exercise in Pregnancy and Outcome. *Clin Obstet Gynecol*. 59(3):591-599.
- Claiborne, A, et al. 2023. A narrative review of exercise dose during pregnancy. *Birth Defects Res*. 115(17):1581-1597.
- Clapp III JF, et al. 1999. Neonatal behavioral profile of the offspring of women who continued to exercise regularly throughout pregnancy. *Am J Obstet Gynecol*. 180(1):91-94.
- Clapp III JF, et al. 2002. Continuing regular exercise during pregnancy: Effect of exercise volume on fetoplacental growth. *Am J Obstet Gynecol*. 186(1):142-147.
- Cordero Y, et al. 2015. Exercise is associated with a reduction in gestational diabetes mellitus. *Med Sci Sports Exerc*. 47(7):1328-1333.
- Fly AD, et al. 1998. Major mineral concentrations in human milk do not change after maximal exercise testing. *Am J Clin Nutr*. 68(2):345-349.
- Kennelly MM, et al. 2002. Exercise-related changes in umbilical and uterine artery waveforms as assessed by Doppler ultrasound scans. *Am J Obstet Gynecol*. 187(3):661-666.
- Kennelly MM, et al. 2002. Fetal heart rate response to strenuous maternal exercise: not a predictor of fetal distress. *Am J Obstet Gynecol*. 187(3):811-816.
- Kołomańska-Bogucka D, Mazur-Bialy AI. 2019. Physical Activity and the Occurrence of Postnatal Depression-A Systematic Review. *Medicina (Kaunas)*. 55(9):560.
- Lederman SA, et al. 1999. Maternal body fat and water during pregnancy: Do they raise infant birth weight? *Am J Obstet Gynecol*; 180(1):235-240.
- Gascoigne EL, et al. 2023. Physical activity and pregnancy outcomes: an expert review. *Am J Obstet Gynecol MFM*; 5(1):100758.
- Gavard J & Artal R. 2008. Effect of Exercise on Pregnancy Outcome. *Clin Obstet Gynecol*; 51(2):467-480.
- Gregg VH & Ferguson JE. 2017. Exercise in Pregnancy. *Clin Sports Med*; 36(4):741-752.
- Greydanus DE & Patel DR. 2002. The female athlete. Before and beyond puberty. *Pediatr Clin North Am*. 49(3):553-580.
- Hicks LE, et al. 2025. Prenatal exercise and its effects on postpartum mental health: systematic review and meta-analysis. *Arch Womens Ment Health*. 28(3):515-524.

- Madsen M, et al. 2007. Leisure time physical exercise during pregnancy and the risk of miscarriage: a study within the Danish National Birth Cohort. *BJOG*; 114(11):1419-1426.
- McLachlan ML, et al. 2026. Case Report: Hyperlactation and Sport Performance in an Elite Marathon Runner. *Clin J Sport Med*. Jan 22. doi: 10.1097/JSM.0000000000001399. Online ahead of print.
- Minguez-Alarcon L, et al. 2014. Physical activity is not related to semen quality in young healthy men. *Fertil Steril*. 102(4): 1103-1109.
- Moolyk AN, et al. 2025. Maternal and fetal responses to acute high-intensity resistance exercise during pregnancy. *Br J Sports Med*. 59(3):159-166.
- Mottola MF, et al. 2018. No. 367-2019. Canadian Guideline for Physical Activity throughout Pregnancy. *J Obstet Gynaecol Can*; 40(11):1528-1537.
- Mussawar M, et al. 2023. The effect of physical activity on fertility: a mini-review. *F S Rep*; 4(2):150-158.
- Oxnard KL, et al. 2026. Patterns in exercise behaviour across pregnancy: a retrospective cohort study of physically active individuals from pre-conception to postpartum. *Eur J Appl Physiol*. Feb 25. doi: 10.1007/s00421-026-06160-6. Online ahead of print.
- Prevett C, et al. 2025. Resistance training in pregnancy: systematic review and meta-analysis of pregnancy, delivery, fetal and pelvic floor outcomes and call to action. *Br J Sports Med*. 59(16):1173-1182.
- Price BB, et al. 2012. Exercise in pregnancy: effect on fitness and obstetric outcomes-a randomized trial. *Med Sci Sports Exerc*; 44(12):2263-2269.
- Redondo-Delgado P, et al. 2025. Effects of strength training on quality of life in pregnant women: A systematic review. *Acta Obstet Gynecol Scand*. 104(7):1231-1243.
- Saccone G, et al. 2026. Exercise in Pregnancy and Risk of Postpartum Depression: A Randomised Controlled Trial. *BJOG*. 133(2):211-217.
- Sanabria-Martínez G, et al. 2019. Effects of physical exercise during pregnancy on mothers' and neonates' health: a protocol for an umbrella review of systematic reviews and metaanalysis of randomised controlled trials. *BMJ Open*; 9(9):e030162.
- Sobal J & Marquart LF. 1994. Vitamin/mineral supplement use among athletes: a review of literature. *Int J Sport Nutr*; 4(4):320-334.
- Suján MJ, et al. 2025. Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING). *BMJ*. 390:e083398.
- Stafne SN, Salvesen et al. 2012. Regular exercise during pregnancy to prevent gestational diabetes: a randomized controlled trial. *Obstet Gynecol*. 119(1):29-36.
- Tomic V, et al. 2013. The effect of maternal exercise during pregnancy on abnormal fetal growth. *Croat Med J*. 54(4):362-368.
- U.S. Department of Health and Human Services. 2018. Physical activity guidelines for Americans. 2nd ed. Washington, DC: DHHS. Available at: <https://health.gov/paguidelines/second-edition/>. [Accessed March 2026].
- Zouradani A, et al. 2015. The effect of physical exercise on postpartum fitness hormone and lipid levels: a randomized controlled trial in primiparous, lactating women. *Arch Gynecol Obstet* 291(3): 525-530.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Risperidone

Selected References:

- Ambresin G, et al. 2004. Olanzapine excretion into breast milk: a case report. *J Clin Psychopharmacol*; 24(1):93-95.
- Aydin B, et al. 2015. Olanzapine and quetiapine use during breastfeeding: Excretion into breast milk and safe breastfeeding strategy. *J Clin Psychopharmacol*; 35:206-208.
- Betcher HK, et. al 2020. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. *J Womens Health* 29(3):310-318.
- Brunner E, et al. 2013. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. *BMC Pharmacology & Toxicology*, 14, 1-8.
- Croke S, et al. 2003. Olanzapine excretion in human breast milk: estimation of infant exposure. *Int J Neuropsychopharmacol*; 5:243-247.
- Damkier P, et al. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically-focused review. *CNS Drugs* 32:351-366.
- Einarson A & Boskovic R. 2009. Use and safety of antipsychotics during pregnancy. *Journal of Psychiatric Practice*; 15, 183-192.
- Eli Lilly and Company. 2025. Zyprexa product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341>. Accessed 31 March 2026.
- Ellfolk M, et al. 2021. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. *Eur J Clin Pharmacol*. 2021; 77(11): 1737-1745.
- Ennis ZN, et al. 2014. Pregnancy exposure to Olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systemic review. *Basic & Clinical Pharmacology & Toxicology*; 116(4), 315-320.
- Friedman SH, et al. 2017. Atypical antipsychotic use and outcomes in an urban maternal mental health service. *Int J Psychiatry Med*; 51(6): 521-533.
- Gilad O, et al. 2011. Outcome of infants exposed to olanzapine during breastfeeding. *Breastfeeding Medicine*; 6, 55-58.
- Habermann F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. *J Clin Psychopharmacol*; 33(4):453-462.
- Heinonen E, et al. 2022. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. *CNS Drugs*; 36:529-
- 539. Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatr*; 73(9):938-946.
- Johnson KC et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy. *Arch Gen Psychiatry*; 69(8):787-794. Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals*. 6(10): 1221-1286.

- Kolli P, et al. 2023. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. *Pharmgenomics Pers Med*; 16:1097-1108.
- Manouilenko I, et al. 2018. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. *Arch Womens Ment Health*; 21(5):587-589
- McKenna K, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *Journal of Clinical Psychiatry*; 4, 444-449.
- Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. *J Clin Psychiatr*; 66:269-270.
- Newport DJ, et al 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. *Am J Psychiatry*; 164(8):1214-20.
- Pacchiarotti I, et al. 2016. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. *Eur Neuropsychopharmacol*; 26:1562-1578.
- Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. *Psychiatry*; 175(6):564-574.
- Reutfors J, et al. 2020 Antipsychotic drug use in pregnancy: A multinational study from 10 countries. *Schizophr Res*; 220:106-115.
- Rubakowski J, et al. 2019. Recommendations of the Poliksh Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. *Psychiatr Pol*; 53(2):263-276.
- Shao P, et al. 2015. Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. *PLoS One*; 10(4).
- Teodorescu A, et al. 2017. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. *BMC Psychiatry*; 17(1):311.
- Vigod SN, et al. 2015. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. *BMJ*; 350:h2298.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Risperidone

Selected References:

- Aljazaf K, et al. 2003. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. *Br J Clin Pharmacol*; 56(1):18- 24.
- Anastasio GD, et al. 1992. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. *J Am Board Fam Pract*; 5(5):527-528.
- Dor S, et al. 2025. Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population-based cohort of pregnancies. *Br J Clin Pharmacol*; 91(6):1834-1841.
- Eglash A. 2014. Treatment of maternal hypergalactia. *Breastfeed Med*; 9:423-425.
- Findlay JW, et al. 1984. Pseudoephedrine and triprolidine in plasma and breast milk of nursing mothers. *Br J Clin Pharmacol*; 18(6):901-906.
- Głowacka K, et al. 2021. Pseudoephedrine-Benefits and Risks. *Int J Mol Sci*; 22(10):5146.
- Heinonen OP, et al. 1977. *Birth Defects and Drugs in Pregnancy*. Littleton, MA: John Wright-PSG. pp 345-356.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol*; 168(5):1393-1399.
- Miller RK. 1992. From the pages of Teratology: vitamin A to pseudoephedrine issues in patient counseling. *Teratology*; 45(4):341-343.
- Pseudoephedrine Drug Label. 2022. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1056d9da-8a3f-4b7a-878e-7f8d45d298cd&audience=consumer>. Accessed 24 March 2026.
- Rosa F. 1993. Personal communication. Cited in: Briggs GG, et al. 2005. *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk*. Seventh Edition. Baltimore, MD: Williams & Wilkins.
- Schatz M, et al. 1997. Asthma and allergy in pregnancy. *Clin Perinatol*; 24(2):407-432.
- Smith CV, et al. 1990. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. *Obstet Gynecol*; 76(5 Pt 1):803-806.
- Smith J, et al. 1994. *Drugs of choice for pregnant women*. In: Koren G. *Maternal-fetal Toxicology. A Clinician's Guide*. 1994. Second Edition. New York NY: Marcel Dekker Inc.
- Soussan C, et al. 2014. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. *Eur J Clin Pharmacol*; 70:1361-1366.
- The American College of Obstetricians and Gynecologists (ACOG). 2025. "Ask ACOG: What medicine can I take for allergies while I'm pregnant?" Available at: <https://www.acog.org/womens-health/experts-and-stories/ask-acog/what-medicine-can-i-take-for-allergies-while-im-pregnant>. Accessed 24 March 2026.
- The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. *Ann Allergy Asthma Immunol*; 84(5):475-480.
- Torfs CP, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. *Teratology* 54(2):84-92.
- Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. *Am J Epidemiol*; 178(2):198-208.
- Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. *Epidemiology*; 14(3):349-354.
- Werler MM, et al. 1992. First trimester maternal medication use in relation to gastroschisis. *Teratology*; 45(4):361-367.
- Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. *Am J*

Epidemiol; 155(1):26-31.

- Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol; 70(6):389-395.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Risperidone

Selected References:

- Anderson KN, et al., 2020. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. *JAMA psychiatry*, 77(12):1246-1255.
- Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. *Hum Psychopharmacol*. 30(3):143-51.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort. *BMJ Open*;7: e013372.
- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. *J Clin Psychiatry*. 65(9):1228-1234.
- Chambers CD, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med*. 354:579-587.
- Dandjinou M, et al. 2019. Antidepressant use during pregnancy and risk of gestational diabetes mellitus: a nested case-control study. *BMJ Open* 9(9): e025908.
- Das N, Chadda RK. 2020. Hyperprolactinemic galactorrhea associated with cefpodoxime in a patient with recurrent depressive disorder on venlafaxine monotherapy: A case report. *J Clin Psychopharmacol*. 40:635-6.
- Desai PH, et al. 2019. Risk of congenital heart disease in newborns with prenatal exposure to anti-depressant medications. *Cureus* 11(5): e4673.

- de Santi F, et al. 2021. Venlafaxine-induced damage to seminiferous epithelium, spermiation, and sperm parameters in rats: A correlation with high estrogen levels. *Andrology*. 9(1):297-311.
- Einarson A, et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry*. 158(10):1728-1730.
- Ferreira E, et al. 2007. Effects of selective reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. *Pediatrics*. 119(1):52-59.
- Furu K, et al. 2015. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *BMJ*. 350:h1798.
- Grzeskowiak LE, et al. 2022. Perinatal antidepressant use and breastfeeding outcomes: Findings from the Norwegian Mother, Father and Child Cohort Study. *Acta Obstet Gynecol Scand*. 101:344-54
- Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*. 74(4): e309-20.
- Holland J, Brown R. 2017. Neonatal venlafaxine discontinuation syndrome: A mini-review. *Eur J Paediatr Neurol*. 21(2):264-8.
- Ilett KF, et al. 2002. Distribution of venlafaxine and its o-desmethyl metabolite in human milk and their effects in breastfed infants. *Br J Clin Pharmacol*. 53:17-22.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. *Acta Paediatr*. 104(4):384-91.
- Kolding L, et al. 2021. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. *BJOG* 128(12):1949-1957.
- Lassen D, et al., 2016. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: A systematic review. *Basic Clin Pharmacol Toxicol*. 118(1):32-6.
- Lennestall R and Kallen B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. *J Clin Psychopharmacol*. 27(6):607-613.
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med*. 160:173-176.
- Marks C, et al. 2021. Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. *Pharmacotherapy*. 41(11):907-914.
- Matthys A, et al. 2014. Psychotropic medication use during pregnancy and lactation: Role of ultrasound assessment. *Donald Sch J Ultrasound Obstet Gynecol*. 8:109-21.
- Newport DJ, et al. 2009. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. *J Clin Psychiatry*. 70(9):1304-10.
- Newport DJ, et al. 2016. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. *J Clin Psychiatry*. 77(11):1538-45.
- Nulman I, et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *Am J Psychiatry*. 169(11):1165-74.
- Polen KN, et al., National Birth Defects Prevention Study. 2013. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. *Birth Defects Res A Clin Mol Teratol*. 97(1):28-35.
- Rai D, et al. 2017. Antidepressants during pregnancy and autism in offspring: population-based cohort study. *BMJ* 358:j2811,
- Richardson JL, et al. 2019. Pregnancy outcomes following maternal venlafaxine use: a prospective observational comparative cohort study. *Reprod Toxicol* 84:108-113,
- Schoretsanitis G, et al. 2019. Antidepressants in breastmilk: comparative analysis of excretion ratios. *Arch Womens Ment Health* 22(3):383-390.
- U.S. Food and Drug Administration. 2023. Effexor XR Drug Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf. Accessed 5 March 2026.
- Wang XY, et al. 2023. Antidepressant use during pregnancy and the risk for gestational diabetes: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med* 36(1):2162817,

- Wartko PD, et al. 2019. Antidepressant continuation in pregnancy and risk of gestational diabetes. *Pharmacoevidemiol Drug Saf* 28(9): 1194-1203.
- Westin AA, et al. 2017. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. *PLoS One*. 12(7):e0181082.
- Yue M, et al. 2023. Pharmacokinetics of Antidepressants in Pregnancy. *J Clin Pharmacol*. 63 Suppl 1: S137-S158.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org)..

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.